RIGL
Rigel Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$607.79M
P/E Ratio
1.70
EPS
$19.29
Beta
1.18
52W High
$52.24
52W Low
$18.14
50-Day MA
$29.82
200-Day MA
$34.18
Dividend Yield
—
Profit Margin
121.50%
Forward P/E
7.30
PEG Ratio
-0.10
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $299.77M |
| Gross Profit (TTM) | $243.41M |
| EBITDA | $126.99M |
| Operating Margin | 20.20% |
| Return on Equity | 174.10% |
| Return on Assets | 22.90% |
| Revenue/Share (TTM) | $16.53 |
| Book Value | $21.64 |
| Price-to-Book | 1.52 |
| Price-to-Sales (TTM) | 2.03 |
| EV/Revenue | 1.691 |
| EV/EBITDA | 3.86 |
| Quarterly Earnings Growth (YoY) | -30.20% |
| Quarterly Revenue Growth (YoY) | 10.30% |
| Shares Outstanding | $18.50M |
| Float | $15.93M |
| % Insiders | 3.25% |
| % Institutions | 94.59% |
Historical Volatility
HV 10-Day
26.77%
HV 20-Day
42.75%
HV 30-Day
59.20%
HV 60-Day
50.72%
HV Rank
50.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($53.20 target)
3
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026